SOLICITATION NOTICE
65 -- Hospital Plastics (Pitcher/Basin/Urinal/Carafe/Bowl) - Technical / Company Requirement Response Document
- Notice Date
- 8/31/2011
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 339113
— Surgical Appliance and Supplies Manufacturing
- Contracting Office
- Defense Logistics Agency, DLA Acquisition Locations, DLA Troop Support - Medical, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
- ZIP Code
- 19111-5096
- Solicitation Number
- MN-1105-33_Hospital_Plastics
- Archive Date
- 10/7/2011
- Point of Contact
- Toni Massenburg, Phone: 571-231-5451, Gail Tucker-Carlisle, Phone: 571-231-5451
- E-Mail Address
-
toni.massenburg@us.army.mil, gail.tucker-carlisle@amedd.army.mil
(toni.massenburg@us.army.mil, gail.tucker-carlisle@amedd.army.mil)
- Small Business Set-Aside
- N/A
- Description
- Responses to this RFIAQ should include all the information as indicated in the FBO. Use this document for all your responses. The Defense Medical Materiel Program Office (DMMPO) Medical Materiel Enterprise Standardization Office (MMESO) announces a Request for Incentive Agreement Quotation (RFIAQ) for the standardization of Hospital Plastics. The MMESO North is the lead MMESO for this project. The primary objective of this program is to standardize the quality of care across the MMESO North, South, West, Pacific, Europe (hereafter referred to as MMESOs) areas of responsibility (AOR) and operational assemblages based on the critical balance of clinical efficacy and value. This Standardization Action (SA) will apply to all MMESOs. It is intended for this initiative to result in the standardization of a technically and clinically preferred product (s) and source for institutional and operational medicine requirements at the best possible price. It is intended for this initiative to result in the reduction of Stock Keeping Units (SKUs) and National Stock Numbers (NSN). It is also intended that standardized products be obtained through the Department of Defense (DoD) Prime Vendor (PV) Program. As an enterprise-wide clinically driven program, vendors and products must meet specific technical requirements plus products must meet or exceed specific clinical performance requirements as a primary consideration. Among vendors who meet the technical requirements and the products that meet or exceed the clinical the clinical preferred threshold, best price will determine selection. It is intended that the selected vendor (s) for this SA support the enterprise goal of medical materiel standardization that combines operational and institutional requirements. The government is seeking a single award for this SA. The major facilities in the MMESOs include, but are not limited to MMESO North: Walter Reed Army Medical Center, National Naval Medical Center, Naval Medical Center Portsmouth, Wright-Patterson Medical Center; MMESO South Wilford Hall Medical Center, Brooke Army Medical Center, Naval Hospital Jacksonville, Martin Army Community Hospital; MMESO West Naval Medical Center San Diego, Madigan Army Medical Center, Irwin Army Community Hospital, Mike O'Callaghan Federal Hospital; MMESO Pacific Tripler Army Medical Center, Honolulu, HI, 18th Medical Group, Kadena AB, Okinawa, US Naval Hospital, Yokosuka, Japan; MMESO Europe Landstuhl Regional Medical Center, Landstuhl, GE, US Naval Hospital, Naples, Italy, the 48th Medical Group, Lakenheath, UK; and Operational U.S. Forces. This standardization action is part of the Medical/Surgical PV program executed by the Defense Logistics Agency (DLA) Troop Support (TS), Directorate of Medical Materiel. To participate, your company must have a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the current Med-Surg PV for each MMESOs Area of Responsibility (AOR), i.e., Cardinal Health, and Owens & Minor. This requirement is pursuant to the DAPA clause by which DAPA holders agree to the standardization process and agree to allow PVs to distribute their products. The Incentive Agreement (IA) resulting from this RFIAQ is a supplement to the PV Program and is not a contract. For additional information regarding DLA TS Medical's PV program please access its web site at https://dmmonline.dscp.dla.mil This IA standardization initiative will be a Three Phase IPP Process: vendor (s) who meets the technical / company requirements in Phase I will be invited to advance and participate Phase II where no-charge products will be provided for clinical evaluation and Phase III where pricing will be required for submittal. Phase II and Phase III will be run concurrently. The resulting IA will be for a base period of two (2) years (24 months) from date of selection with three (3) 12-month "option" periods not to exceed a total of 5 years. Anticipated selection date is December 2011. The selection will be based on the product and vendor that provides the Best Value to the enterprise. Products and vendors that meet or exceed the technical and clinical performance requirements will be considered clinically preferred products and sources. Among vendors who meet the technical requirements and the products that meet or exceed the clinically preferred standard, best price (i.e. lowest Aggregate Post Standardization Cost -- explained in Pricing Analysis in the last paragraph of this document) will determine selection. Point of Contact: Ms. Toni Massenburg, MMESO North, Team Leader, toni.massenburg@us.army.mil, at 571-231-5451 and Gail Tucker-Carlisle, Clinical Analyst, gail.tucker-carlisle@amedd.army.mil. at 571-231-5451. B. Products & Performance Required The MMESOs are seeking product line items in the category of Hospital Plastics. Within the MMESOs, this product line has an estimated annual dollar requirement of $1,196,617.57. This forecast is based on historical prime vendor sales during a recent 12-month period. Based on the recent 12-month usage data, the top fifty five (55) line items of the total one hundred and thirty nine (139) line items, account for 79.7% ($953,493.95) of the total volume in sales ($1,196,617.57) in the MMESOs and are procurement significant. The top high volume usage lines for this project are shown in the Technical/Company Requirements below, consolidated by product type to reduce duplication within the top twelve (12) lines. This represents the line item, or SKU, reduction that is an additional objective of this program. C. Instructions to Vendors Vendors interested in participating in this standardization initiative will provide an initial response to the FBO-posted RFIAQ to Ms. Toni Massenburg, MMESO North, Team Leader, toni.massenburg@us.army.mil, at 571-231-5451 and Gail Tucker-Carlisle, Clinical Analyst, gail.tucker-carlisle@amedd.army.mil. at 571-231-5451. The vendor's initial responses will include detailed information requested in the technical/company requirements listed in the FBO RFIAQ and must also include: (1) Company name and address; (2) Company Point of Contact (POC) (Name and Phone Number, Fax Number, and E-mail address); and (3) Identification of the RFIAQ to which the vendor is responding. Due to the potential for e-mail to be lost in transmission, from network security, etc., vendor is strongly encouraged to confirm with the MMESO North that its initial submission, quote and literature actually arrived at the MMESO North via email. Each submitting vendor is advised to confirm receipt, allowing adequate time for resubmission before the due date/time, should a problem occur with the first submission. Vendor must complete and submit the attached document. Vendor who cannot open the attachments may contact the POC as noted in the FBO RFIAQ before the COB on the date listed for closing and a copy will be provided to vendor via an alternate medium (fax, email or hard copy). Vendors who do not meet the deadline of COB 5:00PM Eastern Standard Time (EST) on the date listed for closing (per the FBO RFIAQ), will be disqualified from further consideration in the standardization initiative. D. Source Selection Procedures The MMESO Joint Product Review Board (JPRB) will serve as the forum for clinical recommendations for product selection, seeking and evaluating opportunities for committed volume purchase agreements, and coordinating logistics efforts in support of DoD Components. The boards are chaired by Designated Senior Logisticians (DSLs) and co-chaired by Designated Senior Clinicians (DSCs) in the MMESO AORs and include clinicians and logisticians for Medical Treatment Facilities (MTFs) within each MMESO. The Clinical Advisory Committee (CAC) members are the deciding officials for this initiative. The MMESO DSLs and DSCs intend to evaluate quotes and select a vendor on initial submissions/quotes. Vendor quotes should contain the vendor's best tiered-pricing discounts off of the vendor's DAPA pricing based on committed volume of 80% of the total requirements of the MTFs in the MMESOs. The MMESO North reserves the right to conduct discussions and request revised quotes, if determined necessary. Phase I Technical / Company Requirements The MMESO CPT will review the responses from the vendors and determine which vendors meet the technical/company requirements and determine acceptability. Vendors must meet the technical requirements for continued consideration in this initiative. Vendors who do not meet the requirements will be disqualified. Failure to provide any requested information or meet any of the technical requirements will disqualify the vendor from further consideration. The vendors who meet the following technical/company requirements will be qualified/invited to participate in the clinical/performance selection and will be requested to submit their best product/price discount quotes via an email communication. All communications of significant acquisition milestones (such as invitations to participate, or notices of disqualification) should be digitally signed. Technical/Company Requirements: During the acquisition planning process, the MMESO CPT validated/approved the technical/company requirements outlined below. The sixteen (16) requirements below must be answered and all supporting documentation provided with the vendor's initial submittal by the response date stated in the FBO announcement. A vendor who does not meet these requirements or who does not submit documentation to support these requirements with initial submittal will be disqualified in Phase I. 1. Vendor must provide a line of Hospital Plastics products that includes at a minimum the specific products identified below for Hospital Plastics as follows: a. PRODUCT DESCRIPTION 1. PITCHER 32OZ W/LID 2. BASIN RECTANGLE 7.4QT GRADUATED 3. URINAL MALE 1000ML GRADUATED 4. CARAFE BEDSIDE W/LID32OZ 5. URINAL MALE 500ML AUTOCLAVABLE 6. BASIN RECTANGLE 6 QT GRADUATED 7. BEDPAN COMMODE STACKABLE 8. BASIN EMESIS 500ML GRADUATED 9. BEDPAN PONTOON 10. BOWL STERILE 32 OZ 11. BASIN ROUND 6QT 12. PAN SPECIMEN COMMODE CONTAINER * Operational usage items are included in this list of Hospital Plastics. b. Vendor must provide a complete itemized list of items supplied (manufacture and/or distribute by brands and descriptions) via excel sheet, and product catalog & literature in response to this RFIAQ with initial submittal. Vendor is required to supply all items listed in all sizes and device type. (A vendor who does not have a complete product line as stated above will be disqualified in Phase I). 2. Vendor must provide plastic products manufactured in any of a wide range of synthetic or semi-synthetic organic solids that are free of PETE and BPA, lead and phalates; are autoclavable and non-reactive to the extreme heat of an autoclave or other sterilizing methodologies. 3. Vendor must provide products that are PVC and latex free/safe, and non-toxic sturdy/non-collapsible material that is easily cleaned with standard, approved hospital cleaning chemicals/solutions and is odor- proof. 4. Vendor must provide products made of material that complies with ISO10993 Biocompatibility of medical devices. 5. Vendor must have urinals that are designed to be used in a lying, sitting or standing position with molded handles, graduation marks to easily measure output, and openings that are wide enough, making them easy to clean. 6. Vendor must provide bed pans that are stackable for easy storage, designed with high rolled fronts and backs with the ability to fit over a commode, and comfortable enough to sit on by bedridden patients in different positions. The design should help prevent spills; have a molded, sturdy grip for easy handling and feature graduation marks to measure output. 7. Vendor must provide heavy-duty molded plastic fracture and contoured bed pans that are ergonomically designed for comfort; have a low-tapered front; and side, loop or grips for easy handling. 8. Vendor must provide wash basins that are rectangular, featuring a large soaking and washing area, and rolled rims for easy carrying. 9. Vendor must provide specimen collector commodes with easy-to-read graduated markings, made of high- impact plastic, and that fit standard toilets. 10. Vendor must provide plastics with an accessible area for easy application of the patient ID label with an indelible marker that does not smear or rub off for patient identification. 11. Vendor must provide plastics that are impervious to staining and are made of color fast dyes. 12. Vendors must have an identified customer service representative available for on-site assessment, on-site instructional sessions (in-services), and on-going clinical support as required at no cost to the government for the Hospital Plastics product line. A vendor must provide a list of customer service representatives with initial submittal. A vendor who cannot provide representatives to support these requirements will be disqualified in Phase I. 13. Vendor must have a DAPA or be in the process of obtaining a DAPA for the Hospital Plastics product line. Vendor must provide DAPA number with initial submittal or provide documentation that DAPA has been applied for with response submittal. A vendor without a DAPA number or who has not applied for a DAPA will be disqualified in Phase I. 14. Vendor must have agreements with the current Med/Surg Prime Vendors for each MMESO AOR, i.e. Cardinal Health and Owens & Minor for Hospital Plastics or be in the process of obtaining Prime Vendor agreements. Vendor must provide documentation to support agreements with initial submittal. A vendor whose products are not available through the Prime Vendors or who has not applied for PV distribution will be disqualified in Phase I. 15. Vendor must submit discounts off of DAPA for all products included in this standardization initiative. (Note: a vendor who fails to submit a discount off of DAPA will be disqualified. Where lower FSS prices are available, DAPA holders are required by previous agreement to provide the FSS price as the DAPA price. A vendor shall not quote FSS prices as the discounted price for purposes of this standardization initiative). A vendor who does not provide discounts off DAPA for ALL products in Phase III will be disqualified. 16. Vendor must indicate country from which each line item is an end product, IAW Trade Agreements Act. Vendors having existing DAPA numbers must also ensure that all DAPA line items/end products in the subject product line list the proper Trade Agreements Act country in the DAPA Management System. Phase II Acceptability Evaluation Clinical Performance Clinical Performance Requirements Following acceptability of the technical/company requirements, the MMESO North, on behalf of the CPT, will request product sample sets from the product group to be sent to the CPT members at the participating MTFs. Vendor will be given 30 calendar days from the issue of the notice in which to deliver the product samples for clinical evaluation at Phase II. Product samples must be shipped to arrive at the designated addresses by 5:00PM local time for each MTF on the 30th calendar day after the notice to ship. Vendor MUST be able to deliver product literature, training materials and evaluation samples to the MMESO North via FedEx or UPS AND to the MMESO Europe via United States Postal Service (USPS) Express Mail and throughout the United States by selected shipment method when requested in Phase II. Vendor who cannot or does not meet this requirement will be disqualified from the standardization process. Vendor must send the MMESO North verification regarding the shipment of literature and samples. This information will include the date of shipment, final delivery date, tracking numbers and the carrier used by the vendor. Vendor will provide ONLY the following no cost product samples for clinical/performance evaluation. Unused samples will not be returned. Six (6) samples of Hospital Plastic listed below are to be provided as samples to each of the evaluation sites as identified in the letters of invitation. ITEMS TO SEND 1. BASIN, EMESIS, PLASTIC, KIDNEY SHAPED, 500 ML 2. BASIN RECTANGULAR 7.5 QUART GRADURATED 3. BEDPAN COMMODE STACKABLE 4. PITCHER, GRADUATED,INSULATED W/STRAW & LID 5. SPECIMEN COLLECTOR COMMODE GRADUATED 6. URINAL Male 1000 ML GRADUATED The clinical/performance evaluation period will last for fourteen (14) calendar days. The acceptability evaluation will be conducted using the below listed requirements with responses as either a "YES" (meets/passes requirements) or "NO" (does not/fails to meet requirements) answers. The MMESO JPRB has established that the Clinically Preferred threshold of products for standardization will be eighty percent (80%) of the requirements questions answered as "YES" (meets/passes requirements). Vendor scoring below the clinically preferred threshold will be disqualified from selection for this standardization initiative. Of those vendors who are qualified as clinically preferred, selection will be based on best price. There will be approximately eight (8) MTFs enterprise wide that will be evaluating products. Clinical/Performance Requirements: During the acquisition planning process, the MMESO CPT validated/approved the clinical/performance requirements outlined below. 1. Patient Safety - CPSC Directive 2002/95/EC; US/CA SB-20/50. The bedpan is ergonomically designed for comfort and its curved, smooth edges do not injure the patient or interfere with the bedpan's function. 2. Patient Safety/Efficiency of Care - CPSC Directive 2002/95/EC; US/CA SB-20/50. The bedpan is sturdy and durable, does not collapse 3. Infection Control - FDA, CDC, APIC. The product has an accessible area for easy application of the patient ID label or marking without smearing or rubbing off. 4. Efficiency of Care - NSF (National Sanitation Foundation) #61 Drinking Water System Components-Health Effects. The graduate markings on drinking cups, basins, pitchers as well as urinals and bedpans are clearly written and easy to read and will not fade or rub off or leach toxins to the consumer when used. 5. Patient and Staff Safety - NSF. The colored/dyed parts of the plastic drinking cup, pitcher or basins do not come off on the patient's body or staff/patient's hand. 6. Infection Control and Patient/Staff Safety - The FDA, CDC, APIC. The lid on the pitcher, cup and urinal is applied easily and remains securely in place with handling. Phase III Pricing Analysis Price Analysis Upon completion of the Phase I - Technical/Company Requirements, a vendor who is found technically acceptable will be qualified /invited to provide product samples and price discount quotes concurrently. A vendor will be given 30 calendar days from the date of pricing requests, to submit IA pricing quotes, in a prescribed electronic spreadsheet format, based upon the requirements of the MMESOs. Pricing must be received at the MMESO North by 5:00 PM EST, thirty (30) calendar days after the issue date of the vendor notice to submit best price quotes. Vendor quotes should contain the vendor's best product matches for the specific products requested in this announcement. The MMESO DSLs and DSCs intend to evaluate quotes and select a vendor on initial submissions/quotes. Vendor quotes should contain the vendor's best tiered-pricing discounts off of the vendor's DAPA pricing for the products identified in this announcement (based on committed volume of 80% of the total requirements of the MTFs in the MMESOs). Price will be analyzed based on the projected Aggregate Post-Standardization costs for each vendor. Aggregate Post-Standardization Cost will be calculated for each vendor by applying the vendors' offered prices to the anticipated annual usage of the enterprise. Unmatched items will be represented in the Post-Standardization Cost at a baseline non-discounted price (current DAPA price of product with highest procurement). Among the products and sources that were determined to be clinically preferred, the best price Aggregate Post-Standardization Cost will be selected.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DLA/J3/DSCP-M/MN-1105-33_Hospital_Plastics/listing.html)
- Place of Performance
- Address: Walter Reed AMC, 6900 Georgia Ave N.W., ATTN: WR-NARMC, Bldg 1 Rm C330, Washington, District of Columbia, 20307, United States
- Zip Code: 20307
- Zip Code: 20307
- Record
- SN02556898-W 20110902/110831235400-5f8fe3384a345b5648bc459056d76b0e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |